Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.

<h4>Background</h4>Adverse outcomes occurring early after antiretroviral therapy (ART) initiation are common in sub-Saharan Africa, despite reports of high levels of ART adherence in this setting. We sought to determine the relationship between very early ART adherence and early adverse...

Full description

Bibliographic Details
Main Authors: Katherine T Steele, Andrew P Steenhoff, Craig W Newcomb, Tumelo Rantleru, Rudo Nthobatsang, Gloria Lesetedi, Scarlett L Bellamy, Jean B Nachega, Robert Gross, Gregory P Bisson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21698283/?tool=EBI
_version_ 1818421453949763584
author Katherine T Steele
Andrew P Steenhoff
Craig W Newcomb
Tumelo Rantleru
Rudo Nthobatsang
Gloria Lesetedi
Scarlett L Bellamy
Jean B Nachega
Robert Gross
Gregory P Bisson
author_facet Katherine T Steele
Andrew P Steenhoff
Craig W Newcomb
Tumelo Rantleru
Rudo Nthobatsang
Gloria Lesetedi
Scarlett L Bellamy
Jean B Nachega
Robert Gross
Gregory P Bisson
author_sort Katherine T Steele
collection DOAJ
description <h4>Background</h4>Adverse outcomes occurring early after antiretroviral therapy (ART) initiation are common in sub-Saharan Africa, despite reports of high levels of ART adherence in this setting. We sought to determine the relationship between very early ART adherence and early adverse outcomes in HIV-infected adults in Botswana.<h4>Methods</h4>This prospective cohort study of 402 ART-naïve, HIV-infected adults initiating ART at a public HIV clinic in Gaborone, Botswana evaluated the relationship between suboptimal early ART adherence and HIV treatment outcomes in the initial months after ART initiation. Early adherence during the interval between initial ART dispensation and first ART refill was calculated using pill counts. In the primary analysis patients not returning to refill and those with adherence <0.95 were considered to have suboptimal early adherence. The primary outcome was death or loss to follow-up during the first 6 months of ART; a secondary composite outcome included the primary outcome plus incident opportunistic illness (OIs) and virologic failure. We also calculated the percent of early adverse outcomes theoretically attributable to suboptimal early adherence using the population attributable risk percent (PAR%).<h4>Results</h4>Suboptimal early adherence was independently associated with loss to follow-up and death (adjusted OR 2.3, 95% CI 1.1-4.8) and with the secondary composite outcome including incident OIs and virologic failure (adjusted OR 2.6, 95% CI 1.4-4.7). However, of those with early adverse outcomes, less than one-third had suboptimal adherence and approximately two-thirds achieved virologic suppression. The PAR% relating suboptimal early adherence and primary and secondary outcomes were 14.7% and 17.7%, respectively.<h4>Conclusions</h4>Suboptimal early adherence was associated with poor outcomes, but most early adverse outcomes occurred in patients with optimal early adherence. Clinical care and research efforts should focus on understanding early adverse outcomes that occur despite optimal adherence.
first_indexed 2024-12-14T13:10:37Z
format Article
id doaj.art-312e17cef2cb473a9a7c9b7c21300360
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-14T13:10:37Z
publishDate 2011-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-312e17cef2cb473a9a7c9b7c213003602022-12-21T23:00:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0166e2001010.1371/journal.pone.0020010Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.Katherine T SteeleAndrew P SteenhoffCraig W NewcombTumelo RantleruRudo NthobatsangGloria LesetediScarlett L BellamyJean B NachegaRobert GrossGregory P Bisson<h4>Background</h4>Adverse outcomes occurring early after antiretroviral therapy (ART) initiation are common in sub-Saharan Africa, despite reports of high levels of ART adherence in this setting. We sought to determine the relationship between very early ART adherence and early adverse outcomes in HIV-infected adults in Botswana.<h4>Methods</h4>This prospective cohort study of 402 ART-naïve, HIV-infected adults initiating ART at a public HIV clinic in Gaborone, Botswana evaluated the relationship between suboptimal early ART adherence and HIV treatment outcomes in the initial months after ART initiation. Early adherence during the interval between initial ART dispensation and first ART refill was calculated using pill counts. In the primary analysis patients not returning to refill and those with adherence <0.95 were considered to have suboptimal early adherence. The primary outcome was death or loss to follow-up during the first 6 months of ART; a secondary composite outcome included the primary outcome plus incident opportunistic illness (OIs) and virologic failure. We also calculated the percent of early adverse outcomes theoretically attributable to suboptimal early adherence using the population attributable risk percent (PAR%).<h4>Results</h4>Suboptimal early adherence was independently associated with loss to follow-up and death (adjusted OR 2.3, 95% CI 1.1-4.8) and with the secondary composite outcome including incident OIs and virologic failure (adjusted OR 2.6, 95% CI 1.4-4.7). However, of those with early adverse outcomes, less than one-third had suboptimal adherence and approximately two-thirds achieved virologic suppression. The PAR% relating suboptimal early adherence and primary and secondary outcomes were 14.7% and 17.7%, respectively.<h4>Conclusions</h4>Suboptimal early adherence was associated with poor outcomes, but most early adverse outcomes occurred in patients with optimal early adherence. Clinical care and research efforts should focus on understanding early adverse outcomes that occur despite optimal adherence.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21698283/?tool=EBI
spellingShingle Katherine T Steele
Andrew P Steenhoff
Craig W Newcomb
Tumelo Rantleru
Rudo Nthobatsang
Gloria Lesetedi
Scarlett L Bellamy
Jean B Nachega
Robert Gross
Gregory P Bisson
Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.
PLoS ONE
title Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.
title_full Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.
title_fullStr Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.
title_full_unstemmed Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.
title_short Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.
title_sort early mortality and aids progression despite high initial antiretroviral therapy adherence and virologic suppression in botswana
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21698283/?tool=EBI
work_keys_str_mv AT katherinetsteele earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT andrewpsteenhoff earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT craigwnewcomb earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT tumelorantleru earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT rudonthobatsang earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT glorialesetedi earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT scarlettlbellamy earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT jeanbnachega earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT robertgross earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana
AT gregorypbisson earlymortalityandaidsprogressiondespitehighinitialantiretroviraltherapyadherenceandvirologicsuppressioninbotswana